News2022-08-19T19:45:46+00:00

News & Events

Monoceros Biosystems and SeekIn Join Forces to Pave the Way for Cutting-Edge AI-Powered Cancer Diagnostics

San Diego, September 21, 2023 – Monoceros Biosystems, a prominent bioinformatics service provider in the United States, is thrilled to announce a strategic partnership with SeekIn, a leading blood testing provider in China, to embark on a groundbreaking collaboration aimed at revolutionizing the field of blood cancer testing. The partnership represents a significant milestone in the quest to advance early cancer detection and disease monitoring through state-of-the-art genomics and bioinformatics [...]

September 21st, 2023|Categories: News|

MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer

Mirati Therapeutics, in collaboration with Monoceros Biosystems and leading academic instituations, published a novel Cancer Discovery article entitled “MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer“ Read Article

August 8th, 2023|Categories: News|

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Mirati Therapeutics, in collaboration with Array BioPharma (Pfizer) and Monoceros Biosystems, published a novel Nature Medicine article entitled "Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor" Read Article

October 10th, 2022|Categories: News|

Monoceros Biosystems Recognized on Inc. 5000 List of Fastest-Growing Private Companies in America

August 19th, 2022|Categories: News|

Monoceros Biosystems has been selected as a top 10 bioinformatics solution provider for 2020 by the CIO Applications magazine

August 18th, 2020|Categories: News|

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Mirati Therapeutics, in collaboration with additional groups including Monoceros Biosystems, published a novel Cancer Discovery article entitled “The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients” Read Article

January 1st, 2020|Categories: News|
Go to Top